Literature DB >> 24913170

Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.

Guiqing Wang1, Sitharthan Kamalakaran2, Abhay Dhand3, Weihua Huang4, Caroline Ojaimi4, Jian Zhuge5, Leslie Lee Yee6, Pramod Mayigowda2, Pavan Kumar Makam Surendraiah4, Nevenka Dimitrova2, John T Fallon7.   

Abstract

Resistance to daptomycin in enterococcal clinical isolates remains rare but is being increasingly reported in the United States and worldwide. There are limited data on the genetic relatedness and microbiological and clinical characteristics of daptomycin-nonsusceptible enterococcal clinical isolates. In this study, we assessed the population genetics of daptomycin-nonsusceptible Enterococcus faecium (DNSE) clinical isolates by multilocus sequence typing (MLST) and whole-genome sequencing analysis. Forty-two nonduplicate DNSE isolates and 43 randomly selected daptomycin-susceptible E. faecium isolates were included in the analysis. All E. faecium isolates were recovered from patients at a tertiary care medical center in suburban New York City from May 2009 through December 2013. The daptomycin MICs of the DNSE isolates ranged from 6 to >256 μg/ml. Three major clones of E. faecium (ST18, ST412, and ST736) were identified among these clinical isolates by MLST and whole-genome sequence-based analysis. A newly recognized clone, ST736, was seen in 32 of 42 (76.2%) DNSE isolates and in only 14 of 43 (32.6%) daptomycin-susceptible E. faecium isolates (P < 0.0001). This report provides evidence of the association between E. faecium clone ST736 and daptomycin nonsusceptibility. The identification and potential spread of this novel E. faecium clone and its association with daptomycin nonsusceptibility constitute a challenge for patient management and infection control at our medical center.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913170      PMCID: PMC4136069          DOI: 10.1128/AAC.02683-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Susceptibility of enterococci to daptomycin is dependent upon testing methodology.

Authors:  Kendall A Bryant; Amity L Roberts; Mark E Rupp; James R Anderson; Elizabeth R Lyden; Paul D Fey; Trevor C Van Schooneveld
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-27       Impact factor: 2.803

2.  Genetic basis for in vivo daptomycin resistance in enterococci.

Authors:  Cesar A Arias; Diana Panesso; Danielle M McGrath; Xiang Qin; Maria F Mojica; Corwin Miller; Lorena Diaz; Truc T Tran; Sandra Rincon; E Magda Barbu; Jinnethe Reyes; Jung H Roh; Elizabeth Lobos; Erica Sodergren; Renata Pasqualini; Wadih Arap; John P Quinn; Yousif Shamoo; Barbara E Murray; George M Weinstock
Journal:  N Engl J Med       Date:  2011-09-08       Impact factor: 91.245

Review 3.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Prevalence of antibiotic resistance in US hospitals.

Authors:  John Edelsberg; Derek Weycker; Rich Barron; Xiaoyan Li; Hongsheng Wu; Gerry Oster; Sejal Badre; Wendy J Langeberg; David J Weber
Journal:  Diagn Microbiol Infect Dis       Date:  2013-11-15       Impact factor: 2.803

5.  Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

Authors:  Mariana Castanheira; Ronald N Jones; Hélio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-07       Impact factor: 2.803

6.  Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy.

Authors:  Truc T Tran; Diana Panesso; Hongyu Gao; Jung H Roh; Jose M Munita; Jinnethe Reyes; Lorena Diaz; Elizabeth A Lobos; Yousif Shamoo; Nagendra N Mishra; Arnold S Bayer; Barbara E Murray; George M Weinstock; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

7.  Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Authors:  Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2009-10       Impact factor: 2.803

8.  De novo daptomycin-nonsusceptible enterococcal infections.

Authors:  Theodoros Kelesidis; Romney Humphries; Daniel Z Uslan; David Pegues
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 16.126

9.  BIGSdb: Scalable analysis of bacterial genome variation at the population level.

Authors:  Keith A Jolley; Martin C J Maiden
Journal:  BMC Bioinformatics       Date:  2010-12-10       Impact factor: 3.169

10.  Clinical experience with daptomycin in Europe: the first 2.5 years.

Authors:  Armando Gonzalez-Ruiz; Andres Beiras-Fernandez; Hans Lehmkuhl; R Andrew Seaton; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2011-01-25       Impact factor: 5.790

View more
  8 in total

1.  Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.

Authors:  Robert J Woods; Twisha S Patel; Jerod L Nagel; Duane W Newton; Andrew F Read
Journal:  Infect Control Hosp Epidemiol       Date:  2018-01-14       Impact factor: 3.254

2.  Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms.

Authors:  Lynn El Haddad; Blake M Hanson; Cesar A Arias; Shashank S Ghantoji; Cynthia P Harb; Mark Stibich; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 9.079

3.  Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus.

Authors:  Matthew H Greene; Bryan D Harris; Whitney J Nesbitt; Marley L Watson; Patty W Wright; Thomas R Talbot; George E Nelson
Journal:  Open Forum Infect Dis       Date:  2018-10-09       Impact factor: 3.835

4.  Evolution and mutations predisposing to daptomycin resistance in vancomycin-resistant Enterococcus faecium ST736 strains.

Authors:  Guiqing Wang; Fan Yu; Henry Lin; Karthikeyan Murugesan; Weihua Huang; Andrew G Hoss; Abhay Dhand; Leslie Y Lee; Jian Zhuge; Changhong Yin; Marisa Montecalvo; Nevenka Dimitrova; John T Fallon
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

5.  Sentinel Surveillance Reveals Emerging Daptomycin-Resistant ST736 Enterococcus faecium and Multiple Mechanisms of Linezolid Resistance in Enterococci in the United States.

Authors:  Amy S Gargis; Lori M Spicer; Alyssa G Kent; Wenming Zhu; Davina Campbell; Gillian McAllister; Thomas O Ewing; Valerie Albrecht; Valerie A Stevens; Mili Sheth; Jasmine Padilla; Dhwani Batra; J Kristie Johnson; Alison Laufer Halpin; J Kamile Rasheed; Christopher A Elkins; Maria Karlsson; Joseph D Lutgring
Journal:  Front Microbiol       Date:  2022-02-01       Impact factor: 5.640

6.  Genomic Surveillance of Vancomycin-Resistant Enterococcus faecium Reveals Spread of a Linear Plasmid Conferring a Nutrient Utilization Advantage.

Authors:  Mathilde Boumasmoud; Vanina Dengler Haunreiter; Tiziano A Schweizer; Lilly Meyer; Bhavya Chakrakodi; Peter W Schreiber; Kati Seidl; Denise Kühnert; Roger D Kouyos; Annelies S Zinkernagel
Journal:  mBio       Date:  2022-03-28       Impact factor: 7.786

7.  Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy.

Authors:  Takashi Matono; Kayoko Hayakawa; Risen Hirai; Akira Tanimura; Kei Yamamoto; Yoshihiro Fujiya; Momoko Mawatari; Satoshi Kutsuna; Nozomi Takeshita; Kazuhisa Mezaki; Norio Ohmagari; Tohru Miyoshi-Akiyama
Journal:  BMC Res Notes       Date:  2016-04-01

8.  Genetic Basis of Emerging Vancomycin, Linezolid, and Daptomycin Heteroresistance in a Case of Persistent Enterococcus faecium Bacteremia.

Authors:  Kieran I Chacko; Mitchell J Sullivan; Colleen Beckford; Deena R Altman; Brianne Ciferri; Theodore R Pak; Robert Sebra; Andrew Kasarskis; Camille L Hamula; Harm van Bakel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.